Recent Patents Filings
Four Patents relating to Mushroom species grown in fermentor for cholesterol and for antidiabetes have been allowed to grant in the USA.
Process for producing, methods and compositions of cholesterol lowering agents from higher Basidiomycetes mushrooms.
Abstract: The present invention describes new and distinct strains Basidiomycetes mushrooms, and a process for growing them in submerged culture. Specifically, the new strains of species of the genus Pleurotus offer superior yields of mushroom biomass and concentrations of biologically active compounds, for example, cholesterol-lowering compounds, lectins, proteins, essential amino acids, vitamins or polysaccharides. The process include use of defined media and a simple one-step procedure of separating the lovastins-containing nutraceuticals from culture broth.
For higher Basidiomycetes Mushrooms grown (as biomass) in submerged culture.
Abstract: The present invention describes new and distinct horticultural varieties of higher Basidiomycetes mushrooms grown in submerged culture. Specifically, the new varieties of species of the genus Pleurotus offer superior yields of mushrooms cell biomass and greater concentrations of the protein rich in essential amino acids, fatty, acids, vitamins and minerals.
Process for producing, methods and compositions of glucuronoxylomannan as nutraceuticals agent form higher Basidiomycetes Mushroom.
Abstract: The present invention describes new and distinct stains of higher Basidiomycetes grown in submerged cultures. Specifically, the new strain of species of the genus Tremella offer superior yields of one-cell biomass and exocellular heteropolysaccharide glucoronoxylomannan, niacin and essential amino acids.
For higher Basidiomycetes Mushrooms grown (as one cell biomass) in submerged culture.
Abstract: The present invention describes new and distinct horticultural varieties of higher Basidiomycetes mushrooms grown in submerged culture. Specially, the new varieties of species of the genus Tremella offer superior yields of mushroom one-cell biomass rich in essential amino acids and vitamins and polysaccharides glucuronoxylomannan.
Other patents developed by the Group have been granted for the US, European countries and Australia include patents for: -
Recent Acquisitions of Intellectual Property for Fungal Therapeutics
The Company has acquired the intellectual property relating to the isolation and characterization of Fungal Growth Hormones called Fungi Flex 1 and Fungi Flex 2 from Dr David Moore and Dr Lily Novak Frazer, two fungal developmental biologists from the University of Manchester, U.K.
Fungal diseases affect plants, animals and man. Knowledge of fungal growth hormones may well open up a very large market for specific remedies for fungal diseases, a new class of fungal therapeutics.
The acquisition strengthens our knowledge-based Biopharmaceutical business, and will enable us to further research into and develop new fungicides for the world market.
We also own certain proprietary information and know-how in techniques and methods relating to the patented inventions and the production of our nutraceutical and biopharmaceutical products.
We own a number of trade marks applications and registrations worldwide - Trade marks comprising and including the words “EVERBLOOM”, “LINZIR” (in the English and Chinese languages) and “Mycomed”, “MycoGlucan” and “MycoVite” cover a variety of health and medical products and food.
Our trade marks are registered or pending registration in a number of countries worldwide. We intend to secure registration of those marks which are still pending acceptance and to preserve the existence of those registrations already obtained through timely renewal.